OBJECTIVE: The study aim was to investigate the methods of breast cancer diagnosis and treatment for women at advanced ages. METHODS: We identified 134 patients ≥ 80 years old treated for breast cancer. Data included patient and tumor characteristics, treatment, and outcomes. RESULTS: Of 134 women ≥ 80 years old, 146 breast cancers were diagnosed. Sixty-five (45%) were detected by mammography. Surgical therapy included partial mastectomy in 50% and mastectomy in 50%. Although 12 (9%) women had no axillary staging, 22 (16%) underwent axillary lymph node dissection for node-negative disease. Of 73 patients undergoing partial mastectomy, 34 (47%) received adjuvant radiation. Of 113 cancers with known estrogen receptor (ER) status, 83% were ER positive; 95% received endocrine therapy. Fourteen (10%) received adjuvant chemotherapy. Eleven (8%) were Her-2 neu-amplified; one patient received adjuvant trastuzumab. At follow-up, 87 (65%) patients were alive without evidence of disease, while 6 (4%) died of breast cancer. CONCLUSIONS: Breast cancer in women ≥ 80 years is more likely to be early-stage with favorable tumor biology. While most women eligible for anti-estrogen therapy received it, adjuvant radiation, chemotherapy, and/or trastuzumab were utilized infrequently. Despite these variations, older women with breast cancer are unlikely to suffer breast cancer-related mortality.
OBJECTIVE: The study aim was to investigate the methods of breast cancer diagnosis and treatment for women at advanced ages. METHODS: We identified 134 patients ≥ 80 years old treated for breast cancer. Data included patient and tumor characteristics, treatment, and outcomes. RESULTS: Of 134 women ≥ 80 years old, 146 breast cancers were diagnosed. Sixty-five (45%) were detected by mammography. Surgical therapy included partial mastectomy in 50% and mastectomy in 50%. Although 12 (9%) women had no axillary staging, 22 (16%) underwent axillary lymph node dissection for node-negative disease. Of 73 patients undergoing partial mastectomy, 34 (47%) received adjuvant radiation. Of 113 cancers with known estrogen receptor (ER) status, 83% were ER positive; 95% received endocrine therapy. Fourteen (10%) received adjuvant chemotherapy. Eleven (8%) were Her-2 neu-amplified; one patient received adjuvant trastuzumab. At follow-up, 87 (65%) patients were alive without evidence of disease, while 6 (4%) died of breast cancer. CONCLUSIONS:Breast cancer in women ≥ 80 years is more likely to be early-stage with favorable tumor biology. While most women eligible for anti-estrogen therapy received it, adjuvant radiation, chemotherapy, and/or trastuzumab were utilized infrequently. Despite these variations, older women with breast cancer are unlikely to suffer breast cancer-related mortality.
Authors: Vittal Sree Rama Rao; Jainudeen K A Jameel; Tapan K Mahapatra; Penelope L McManus; John N Fox; Philip J Drew Journal: Breast J Date: 2007 Jul-Aug Impact factor: 2.431
Authors: W J Louwman; J C M Vulto; R H A Verhoeven; G A P Nieuwenhuijzen; J W W Coebergh; A C Voogd Journal: Eur J Cancer Date: 2007-09-17 Impact factor: 9.162
Authors: Roberto Gennari; Giuseppe Curigliano; Nicole Rotmensz; Chris Robertson; Marco Colleoni; Stefano Zurrida; Franco Nolè; Filippo de Braud; Laura Orlando; Maria Cristina Leonardi; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Giuseppe Renne; Saverio Cinieri; Riccardo A Audisio; Alberto Luini; Roberto Orecchia; Giuseppe Viale; Aron Goldhirsch Journal: Cancer Date: 2004-09-15 Impact factor: 6.860
Authors: Igor M Poltinnikov; Shari B Rudoler; Yevgen Tymofyeyev; Julia Kennedy; Pramila R Anne; Walter J Curran Journal: Am J Clin Oncol Date: 2006-02 Impact factor: 2.339
Authors: Grace L Smith; Ying Xu; Ya-Chen T Shih; Sharon H Giordano; Benjamin D Smith; Kelly K Hunt; Eric A Strom; George H Perkins; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Am Coll Surg Date: 2009-08-20 Impact factor: 6.113
Authors: Julia Frebault; Carmen Bergom; Chandler S Cortina; Monica E Shukla; Yiwen Zhang; Chiang-Ching Huang; Amanda L Kong Journal: Clin Breast Cancer Date: 2021-07-16 Impact factor: 3.225
Authors: Nam P Nguyen; Ulf Karlsson; Eromosele Oboite; Julio Alvarenga; Juan Godinez; Alice Zamagni; Micaela Motta; Satya Bose; Vincent Vinh-Hung Journal: Transl Cancer Res Date: 2020-01 Impact factor: 1.241